News Quantified

RPRX – royalty pharma plc - class a ordinary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln [Seeking Alpha]

Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million

Royalty Pharma (NASDAQ:RPRX) was given a new $45.00 price target on by analysts at Leerink Partners.

Royalty Pharma (NASDAQ:RPRX) had its price target raised by analysts at TD Cowen from $42.00 to $45.00. They now have a "buy" rating on the stock.

Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at Cowen Inc.

Form 8-K Royalty Pharma plc For: Dec 20

Form 4 Royalty Pharma plc For: Dec 19 Filed by: Urist Marshall

Form 8-K Royalty Pharma plc For: Dec 19

Form 4 Royalty Pharma plc For: Dec 17 Filed by: Lloyd George W.

Form 4 Royalty Pharma plc For: Dec 16 Filed by: Urist Marshall

Top News Gainers

12/12 Repros Therapeutics Inc.® Announces Acquisition by Allergan plc 49.1%

12/15 Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism; shares down 10% after hours [Seeking Alpha] 7.0%

1/4 Form SC TO-T/A REPROS THERAPEUTICS INC. Filed by: Allergan plc 5.3%

1/30 Form SC TO-T/A REPROS THERAPEUTICS INC. Filed by: Allergan plc 2.3%

12/21 Biotech Stocks' Research Reports Released on Repros Therapeutics, Aldeyra Therapeutics, Neothetics, and BioLine Rx 2.0%

12/29 Form SC TO-T REPROS THERAPEUTICS INC. Filed by: Allergan plc 0.9%

12/14 Biotech Analysis Central Pharma News: AbbVie And Roche Stellar Data, Aduro Pulls The Cord, Allergan's Bargain Bin Buy [Seeking Alpha] 0.3%

1/19 Form SC 14D9/A REPROS THERAPEUTICS INC. Filed by: REPROS THERAPEUTICS INC. 0.2%

1/9 Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Repros Therapeutics Inc. In The Southern District Of Texas Houston Division 0.1%

12/12 REPROS THERAPEUTICS INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout 0.0%

Top News Decliners

1/31 Form POS AM REPROS THERAPEUTICS INC. -6.9%

12/15 Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency -5.6%

11/20 Repros Therapeutics Inc. (NASDAQ: RPRX) had its price target lowered by analysts at S&P Equity Research from $0.49 to $0.39. -3.4%

1/26 BRIEF-Repros Announces Negative Opinion From The EMA For Enclomiphene [Reuters] -1.3%

12/12 Form 8-K REPROS THERAPEUTICS INC. For: Dec 11 -0.8%

12/29 Form SC 14D9 REPROS THERAPEUTICS INC. Filed by: REPROS THERAPEUTICS INC. -0.5%

1/2 BRIEF-MMCAP International Reports An 8.48 Pct Passive Stake In Repros Therapeutics [Reuters] -0.3%

12/13 Form SC14D9C REPROS THERAPEUTICS INC. Filed by: REPROS THERAPEUTICS INC. -0.2%

1/26 European advisory group backs seven medicines for approval, rejects Repros' enclomiphene [Seeking Alpha] -0.1%

1/5 Form SC TO-T/A REPROS THERAPEUTICS INC. Filed by: Allergan plc -0.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day